The company priced 3.7 million units of securities at $1.35 per share, according to an Oct. 7 news release.
Bone Biologics also granted underwriters the option to purchase up to 566,666 additional shares of common stock.
Next Up in Biologics
-
Miach Orthopaedics' BEAR (bridge-enhanced ACL restoration) implant is now available to treat children and adolescents with anterior cruciate ligament tears…
-
Atreon Orthopedics earned expanded FDA 510(k) clearance for its Rotium bioreabsorbable wick, according to a March 6 news release.
-
Spine biologics is gaining more interest, and its innovation will be rooted in tailored patient care, Craig McMains, MD, said.